Met Antibody (H-10): sc-514149
- Met Antibody (H-10) is a mouse monoclonal IgG2b κ, cited in 2 publications, provided at 200 µg/ml
- specific for an epitope mapping between amino acids 1375-1391 within a C-terminal cytoplasmic domain of Met of human origin
- recommended for detection of Met of human origin by WB, IP, IF, IHC(P) and ELISA
- See Met (D-4): sc-514148 for Met antibody conjugates, including AC, HRP, FITC, PE, Alexa Fluor® 488, 594, 647, 680 and 790.
- m-IgG2b BP-HRP and m-IgGκ BP-HRP are the preferred secondary detection reagents for Met Antibody (H-10) for WB and IHC(P) applications. These reagents are now offered in bundles with Met Antibody (H-10) (see ordering information below).
QUICK LINKS
SEE ALSO...
Met Antibody (H-10) is a mouse monoclonal IgG2b antibody that detects c-Met in human samples through various applications including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and enzyme-linked immunosorbent assay (ELISA). Anti-c-Met antibody (H-10) specifically targets c-Met, a crucial transmembrane receptor that plays a significant role in cellular signaling pathways, particularly in relation to hepatocyte growth factor, a key player in liver regeneration. c-Met is primarily located on the cell surface, where c-Met mediates important biological processes such as cell proliferation, survival, and migration. This localization enables rapid response to extracellular signals, facilitating the regulation of tissue repair and regeneration. Dysregulation of c-Met signaling has been implicated in various cancers, making c-Met an important target for therapeutic intervention. c-Met monoclonal antibody (H-10) effectively detects c-Met in different experimental contexts, providing valuable insights into cancer progression mechanisms and potential treatment strategies.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
Met Antibody (H-10) References:
- Met receptor dynamics and signalling. | Hammond, DE., et al. 2004. Curr Top Microbiol Immunol. 286: 21-44. PMID: 15645709
- Targeting the MET oncogene in cancer and metastases. | Stella, GM., et al. 2010. Expert Opin Investig Drugs. 19: 1381-94. PMID: 20868306
- MET inhibition in lung cancer. | Menis, J., et al. 2013. Transl Lung Cancer Res. 2: 23-39. PMID: 25806202
- Regulation of the MET oncogene: molecular mechanisms. | Zhang, J. and Babic, A. 2016. Carcinogenesis. 37: 345-55. PMID: 26905592
- MET expression during prostate cancer progression. | Verhoef, EI., et al. 2016. Oncotarget. 7: 31029-36. PMID: 27105539
- MET mutation causes muscular dysplasia and arthrogryposis. | Zhou, H., et al. 2019. EMBO Mol Med. 11: PMID: 30777867
- MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis. | Liang, H. and Wang, M. 2020. Onco Targets Ther. 13: 2491-2510. PMID: 32273721
- Resistance to MET inhibition in MET-dependent NSCLC and therapeutic activity after switching from type I to type II MET inhibitors. | Riedel, R., et al. 2023. Eur J Cancer. 179: 124-135. PMID: 36521334
- MET Fusions in NSCLC: Clinicopathologic Features and Response to MET Inhibition. | Riedel, R., et al. 2024. J Thorac Oncol. 19: 160-165. PMID: 37429463
- MET Inhibitor Capmatinib Radiosensitizes MET Exon 14-Mutated and MET-Amplified Non-Small Cell Lung Cancer. | Ramesh, S., et al. 2024. Int J Radiat Oncol Biol Phys. 118: 1379-1390. PMID: 37979706
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Met Antibody (H-10) | sc-514149 | 200 µg/ml | $322.00 | |||
Met Antibody (H-10): m-IgGκ BP-HRP Bundle | sc-536232 | 200 µg Ab; 40 µg BP | $361.00 | |||
Met Antibody (H-10): m-IgG2b BP-HRP Bundle | sc-549527 | 200 µg Ab; 10 µg BP | $361.00 | |||
Met (H-10) Neutralizing Peptide | sc-514149 P | 100 µg/0.5 ml | $69.00 |